Studies Show Links Between Gabapentin and Cognitive Decline and Dementia
Gabapentin is a prescription medication, gamma aminobutyric acid (GABA) analogue, that reduces the excitability of neurons. It is used to control and prevent partial seizures, to relieve neuralgia, and to treat restless legs syndrome. It’s also used off label to address anxiety disorders, migraines, insomnia, drug and alcohol withdrawal symptoms, and for non-approved pain problems like nerve pain from sciatica. The brand names of gabapentin are Neurontin, Horizant, and Gralise. Some states have classified gabapentin as a Schedule V controlled substance due to the number of deaths from overdose, but prescriptions are climbing anyway. Recent studies have shown that there may be cognitive dangers in using gabapentin, including the risk of dementia. If you believe your cognitive decline (or your loved one’s cognitive decline) is the result of gabapentin use, you should call the seasoned Chicago-based product liability lawyers of Moll Law Group.
Contact Moll Law Group About Your Gabapentin Claim
Evidence has accumulated that gabapentin use may come with cognitive risks; studies demonstrate that there are increased rates of cognitive decline and dementia in those patients that use the prescription drug. For instance, one study found that those treated for chronic low backpain with six or more gabapentin prescriptions had an 85% higher risk of mild cognitive impairment and 29% higher risk of dementia within 10 years compared to those who had no gabapentin prescriptions after being diagnosed. This higher risk wasn’t limited to the older patients—even adults between ages 35-49 had over two times the risk of dementia and over three times the risk of mild cognitive impairment than their peers in the group that didn’t take gabapentin. There was elevated danger of cognitive impairment and dementia for those between ages 50-64, too.
A Case Western study also implies a connection between gabapentin and increased risk of dementia in otherwise cognitively healthy adults. And in Frontiers in Pharmacology, a study compared the neurocognitive changes between (1) 480 adults who were 65 or older but not cognitively impaired who started taking gabapentin and (2) a group of 4320 adults that didn’t take the drug. The researchers determined that the gabapentin group had 1.5 to 1.9 times the chances of developing cognitive decline after a year compared with the non-gabapentin group. The same lead scientist conducted another comparative study, examining those adults who did have cognitive impairment when they started taking gabapentin; in those cases, the gabapentin use wasn’t significantly linked with cognitive decline within two years.
Illinois Injury and Mass Tort Lawyer Blog





On August 3, 2026, plaintiffs filed
In June, the Consumer Product Safety Commission (CPSC) and Galanz Americas Limited announced a recall of the latter’s
In August, Louisville, Featherlite, Lite & Century Attic Stairway Ladders with gas struts were
On August 6, 2026, OKK Trading
On June 11, 2026,
On June 4, TOMY recalled its 8 oz.
On June 11, 2026, Joyin, the manufacturer of Sloosh dive sticks
Recently, a number of lawsuits against AI companies have sought to use product liability theory and strategy to hold them accountable for injuries to consumers, especially minors. Some pundits have called this a Big Tobacco moment— using product liability law in this context is novel; but these theories were also successfully used to go after big tobacco companies in the 1990s and to achieve multibillion dollar settlements and changes to cigarette marketing. One of the most prominent pieces of current AI litigation is Florida’s
AngioDynamics port catheters are devices that give patients long-term access to their veins for treatments like chemotherapy. Unfortunately, the Food and Drug Administration (FDA) received hundreds of reports of failures. Many lawsuits were filed claiming that the AngioDynamics’ and its subsidiary Navilyst Medical’s port catheters caused serious injuries, and these were consolidated into federal